These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15597023)

  • 1. Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation.
    Fredrick RT; Hassanein TI
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S14-22. PubMed ID: 15597023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
    Gonzalez SA; Jacobson IM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S22-6. PubMed ID: 15468614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Collantes RS; Younossi ZM
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP; Younossi ZM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
    Behler CM; Vittinghoff E; Lin F; Chung RT; Peters MG; Robbins GK; Volberding PA
    Clin Infect Dis; 2007 May; 44(10):1375-83. PubMed ID: 17443478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; McNicholl IR
    Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office.
    Tien PC; ;
    Am J Gastroenterol; 2005 Oct; 100(10):2338-54. PubMed ID: 16181388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
    Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
    J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
    Mandorfer M; Neukam K; Reiberger T; Payer BA; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Meyer-Olson D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M
    AIDS; 2013 Nov; 27(17):2707-14. PubMed ID: 23835502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
    Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Puoti M; Orkin C; Hunt SL
    J Infect Dis; 2015 Aug; 212(3):367-77. PubMed ID: 25583164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-containing and interferon-free HCV therapy for HIV-infected patients.
    Sulkowski MS
    Semin Liver Dis; 2014 Feb; 34(1):72-8. PubMed ID: 24782260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
    Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.